BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ang SF, Ng ES, Li H, Ong YH, Choo SP, Ngeow J, Toh HC, Lim KH, Yap HY, Tan CK, Ooi LL, Cheow PC, Chung AY, Chow PK, Foo KF, Tan MH. The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma. PLoS One. 2015;10:e0118658. [PMID: 25830231 DOI: 10.1371/journal.pone.0118658] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Mao S, Yu X, Shan Y, Fan R, Wu S, Lu C. Albumin-Bilirubin (ALBI) and Monocyte to Lymphocyte Ratio (MLR)-Based Nomogram Model to Predict Tumor Recurrence of AFP-Negative Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1355-65. [PMID: 34805014 DOI: 10.2147/JHC.S339707] [Reference Citation Analysis]
2 Lai YS, Cheng CC, Lee MT, Chao WT, Lai YC, Hsu YH, Liu YH. The Prognostic Value of Cytokeratin and Sal-Like Protein 4 Expression in Hepatocellular Carcinoma and Intra-Hepatic Cholangiocarcinoma in Taiwan. Int J Med Sci 2018;15:1746-56. [PMID: 30588199 DOI: 10.7150/ijms.28440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
3 Beumer BR, Buettner S, Galjart B, van Vugt JLA, de Man RA, IJzermans JNM, Koerkamp BG. Systematic review and meta-analysis of validated prognostic models for resected hepatocellular carcinoma patients. Eur J Surg Oncol 2021:S0748-7983(21)00738-1. [PMID: 34602315 DOI: 10.1016/j.ejso.2021.09.012] [Reference Citation Analysis]
4 Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF, Jia J, Tian Q, Aggarwal R, Muljono DH, Omata M, Ooka Y, Han KH, Lee HW, Jafri W, Butt AS, Chong CH, Lim SG, Pwu RF, Chen DS. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2020;5:167-228. [PMID: 31852635 DOI: 10.1016/s2468-1253(19)30342-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 34] [Article Influence: 19.3] [Reference Citation Analysis]
5 Xu W, Li R, Liu F. Novel Prognostic Nomograms for Predicting Early and Late Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy. Cancer Manag Res. 2020;12:1693-1712. [PMID: 32214844 DOI: 10.2147/cmar.s241959] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
6 Zheng J, Seier K, Gonen M, Balachandran VP, Kingham TP, D'Angelica MI, Allen PJ, Jarnagin WR, DeMatteo RP. Utility of Serum Inflammatory Markers for Predicting Microvascular Invasion and Survival for Patients with Hepatocellular Carcinoma. Ann Surg Oncol 2017;24:3706-14. [PMID: 28840521 DOI: 10.1245/s10434-017-6060-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
7 Huang Y, Chen H, Zeng Y, Liu Z, Ma H, Liu J. Development and Validation of a Machine Learning Prognostic Model for Hepatocellular Carcinoma Recurrence After Surgical Resection. Front Oncol 2020;10:593741. [PMID: 33598425 DOI: 10.3389/fonc.2020.593741] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Tu HB, Chen LH, Huang YJ, Feng SY, Lin JL, Zeng YY. Novel model combining contrast-enhanced ultrasound with serology predicts hepatocellular carcinoma recurrence after hepatectomy. World J Clin Cases 2021; 9(24): 7009-7021 [PMID: 34540956 DOI: 10.12998/wjcc.v9.i24.7009] [Reference Citation Analysis]
9 Zhang F, Wang Y, Chen G, Li Z, Xing X, Putz-Bankuti C, Stauber RE, Liu X, Madl T. Growing Human Hepatocellular Tumors Undergo a Global Metabolic Reprogramming. Cancers (Basel) 2021;13:1980. [PMID: 33924061 DOI: 10.3390/cancers13081980] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Ao L, Song X, Li X, Tong M, Guo Y, Li J, Li H, Cai H, Li M, Guan Q, Yan H, Guo Z. An individualized prognostic signature and multi‑omics distinction for early stage hepatocellular carcinoma patients with surgical resection. Oncotarget 2016;7:24097-110. [PMID: 27006471 DOI: 10.18632/oncotarget.8212] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
11 Guo J, Lan Z. PHD2 acts as an oncogene through activation of Ras/Raf/MEK/ERK and JAK1/STAT3 pathways in human hepatocellular carcinoma cells. Artif Cells Nanomed Biotechnol 2020;48:37-45. [PMID: 31852247 DOI: 10.1080/21691401.2019.1699806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Feng Y, Hao F. Hansenia weberbaueriana (Fedde ex H.Wolff) Pimenov & Kljuykov Extract Suppresses Proliferation of HepG2 Cells via the PTEN-PI3K-AKT Pathway Uncovered by Integrating Network Pharmacology and Iin Vitro Experiments. Front Pharmacol 2021;12:620897. [PMID: 33967754 DOI: 10.3389/fphar.2021.620897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ang SF, Ng ES, Li H, Ong YH, Choo SP, Ngeow J, Toh HC, Lim KH, Yap HY, Tan CK, Ooi LL, Cheow PC, Chung AY, Chow PK, Foo KF, Tan MH. Correction: The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma. PLoS One 2015;10:e0128058. [PMID: 25970288 DOI: 10.1371/journal.pone.0128058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
14 Shuyao W, Mingyang B, Feifei M, Xiaoqin H. CK19 Predicts Recurrence and Prognosis of HBV Positive HCC. J Gastrointest Surg 2021. [PMID: 34506016 DOI: 10.1007/s11605-021-05107-w] [Reference Citation Analysis]
15 Ang SF, Ng ES, Li H, Ong YH, Choo SP, Ngeow J, Toh HC, Lim KH, Yap HY, Tan CK, Ooi LL, Cheow PC, Chung AY, Chow PK, Foo KF, Tan MH. Correction: The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma. PLoS One. 2015;10:e0128058. [PMID: 25970288 DOI: 10.1371/journal.pone.012805] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Burt AD, Alves V, Bedossa P, Clouston A, Guido M, Hübscher S, Kakar S, Ng I, Park YN, Reeves H, Wyatt J, Yeh MM, Ellis DW. Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology 2018;73:369-85. [DOI: 10.1111/his.13520] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
17 Wu Q, Liu TY, Hu BC, Li X, Wu YT, Sun XT, Jiang XW, Wang S, Qin XC, Ding HW, Zhao QC. CK-3, A Novel Methsulfonyl Pyridine Derivative, Suppresses Hepatocellular Carcinoma Proliferation and Invasion by Blocking the PI3K/AKT/mTOR and MAPK/ERK Pathways. Front Oncol 2021;11:717626. [PMID: 34395292 DOI: 10.3389/fonc.2021.717626] [Reference Citation Analysis]
18 Fu YP, Yi Y, Huang JL, Jing CY, Sun J, Ni XC, Lu ZF, Cao Y, Zhou J, Fan J, Qiu SJ. Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection. Oncologist 2017;22:561-9. [PMID: 28438885 DOI: 10.1634/theoncologist.2016-0231] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
19 Neri L, Lasa M, Elosegui-Artola A, D'Avola D, Carte B, Gazquez C, Alve S, Roca-Cusachs P, Iñarrairaegui M, Herrero J, Prieto J, Sangro B, Aldabe R. NatB-mediated protein N-α-terminal acetylation is a potential therapeutic target in hepatocellular carcinoma. Oncotarget 2017;8:40967-81. [PMID: 28498797 DOI: 10.18632/oncotarget.17332] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
20 Kang TW, Rhim H, Lee J, Song KD, Lee MW, Kim YS, Lim HK, Jang KM, Kim SH, Gwak GY, Jung SH. Magnetic resonance imaging with gadoxetic acid for local tumour progression after radiofrequency ablation in patients with hepatocellular carcinoma. Eur Radiol 2016;26:3437-46. [PMID: 26747262 DOI: 10.1007/s00330-015-4190-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
21 Chan EE, Chow PK. A review of prognostic scores after liver resection in hepatocellular carcinoma: the MSKCC, SLICER and SSCLIP scores. Jpn J Clin Oncol 2017;47:287-93. [PMID: 27980082 DOI: 10.1093/jjco/hyw185] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Koda M, Tanaka S, Takemura S, Shinkawa H, Kinoshita M, Hamano G, Ito T, Kawada N, Shibata T, Kubo S. Long-Term Prognostic Factors after Hepatic Resection for Hepatitis C Virus-Related Hepatocellular Carcinoma, with a Special Reference to Viral Status. Liver Cancer 2018;7:261-76. [PMID: 30319984 DOI: 10.1159/000486902] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
23 Yilma M, Saxena V, Mehta N. Models to Predict Development or Recurence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Hepatic Fibrosis. Curr Gastroenterol Rep 2022. [PMID: 35142988 DOI: 10.1007/s11894-022-00835-8] [Reference Citation Analysis]
24 Cheng Z, Yang P, Lei Z, Zhang B, Si A, Yan Z, Xia Y, Li J, Wang K, Hartmann D, Hüser N, Lau WY, Shen F. Nomograms for prediction of long-term survival in elderly patients after partial hepatectomy for hepatocellular carcinoma. Surgery 2017;162:1231-40. [PMID: 29033225 DOI: 10.1016/j.surg.2017.07.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
25 Feng J, Zhu R, Chang C, Yu L, Cao F, Zhu G, Chen F, Xia H, Lv F, Zhang S, Sun L. CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection. PLoS One. 2016;11:e0151501. [PMID: 26977595 DOI: 10.1371/journal.pone.0151501] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
26 Zheng J, Chou JF, Gönen M, Vachharajani N, Chapman WC, Majella Doyle MB, Turcotte S, Vandenbroucke-Menu F, Lapointe R, Buettner S, Groot Koerkamp B, Ijzermans JNM, Chan CY, Goh BKP, Teo JY, Kam JH, Jeyaraj PR, Cheow PC, Chung AYF, Chow PKH, Ooi LLPJ, Balachandran VP, Kingham TP, Allen PJ, D'Angelica MI, DeMatteo RP, Jarnagin WR, Lee SY. Prediction of Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Resection: Validation of a Clinical Risk Score in an International Cohort. Ann Surg 2017;266:693-701. [PMID: 28650354 DOI: 10.1097/SLA.0000000000002360] [Cited by in Crossref: 40] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
27 Zheng J, Kuk D, Gönen M, Balachandran VP, Kingham TP, Allen PJ, D'Angelica MI, Jarnagin WR, DeMatteo RP. Actual 10-Year Survivors After Resection of Hepatocellular Carcinoma. Ann Surg Oncol 2017;24:1358-66. [PMID: 27921192 DOI: 10.1245/s10434-016-5713-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 7.3] [Reference Citation Analysis]
28 Wang Y, Tan PY, Handoko YA, Sekar K, Shi M, Xie C, Jiang XD, Dong QZ, Goh BKP, Ooi LL, Gao Z, Hui KM. NUF2 is a valuable prognostic biomarker to predict early recurrence of hepatocellular carcinoma after surgical resection. Int J Cancer. 2019;145:662-670. [PMID: 30653265 DOI: 10.1002/ijc.32134] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
29 Li P, Wu L, Li Z, Li J, Ye W, Shi Z, Xu Z, Zhu C, Ye H, Liu Z, Liang C. Spleen Radiomics Signature: A Potential Biomarker for Prediction of Early and Late Recurrences of Hepatocellular Carcinoma After Resection. Front Oncol 2021;11:716849. [PMID: 34485152 DOI: 10.3389/fonc.2021.716849] [Reference Citation Analysis]
30 Muthiah M, H Chong C, G Lim S. Liver Disease in Singapore. Euroasian J Hepatogastroenterol 2018;8:66-8. [PMID: 29963466 DOI: 10.5005/jp-journals-10018-1262] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]